CRBP
NASDAQ
US
Corbus Pharmaceuticals Holdings, Inc. - Common Stock
$10.17
▲ +$0.19
(+1.90%)
Vol 236K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$142.9M
ROE
-57.1%
Margin
-2838.7%
D/E
0.00
Beta
2.86
52W
$5–$21
Wall Street Consensus
16 analysts · Apr 20266
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
93.8%
Buy Rating
Price Chart
Similar Stocks
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
CRBU
Caribou Biosciences Inc
$148.6M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
GALT
Galectin Therapeutics Inc
$268.2M
ACHV
Achieve Life Sciences Inc
$264.6M
SGMT
Sagimet Biosciences Inc
$183.5M
CNTN
Canton Strategic Holdings Inc
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.61 | $-1.25 | +$0.36 |
| Sep 2025 | $-1.74 | $-1.90 | $-0.16 |
| Jun 2025 | $-1.54 | $-1.44 | +$0.10 |
| Mar 2025 | $-1.31 | $-1.39 | $-0.08 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$13.8M | -$9.5M | -$17.0M | -$17.7M | -$23.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -43.6% | -43.6% | -43.6% | -43.6% | -43.6% | -57.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -2838.7% | -2838.7% | -2838.7% | -2838.7% | -2838.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.21 | 9.21 | 9.21 | 9.21 | 9.21 | 6.31 |
Key Ratios
ROA (TTM)
-50.9%
P/S (TTM)
92.18
P/B
1.0
EPS (TTM)
$-5.51
CF/Share
$-10.98
52W High
$20.56
52W Low
$4.64
$4.64
52-Week Range
$20.56
Financial Health
Free Cash Flow
-$15.6M
Net Debt
-$24.9M
Cash
$27.0M
Total Debt
$2.0M
As of Sep 30, 2025
How does CRBP compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRBP valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
92.2
▲
617%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
1.0
▼
59%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRBP profitability vs Biotechnology peers
ROE
-57.1%
▲
15%
above
peers
(-67.3%)
vs Peers
vs Industry
In line
Net margin
-2838.7%
▼
890%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-50.9%
▼
9%
below
peers
(-46.7%)
vs Peers
vs Industry
In line
CRBP financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
6.3
▲
42%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.9
▲
195%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CRBP fundamentals radar
CRBP
Peer median
Industry
CRBP profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRBP vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
SMETHURST DOMINIC
Officer · Mar 02
6097 shs
HODGSON IAN
Chief Operating Officer · Feb 17
847 shs
MORAN SEAN F
Chief Financial Officer · Feb 13
4701 shs
COHEN YUVAL
Chief Executive Officer · Feb 13
13871 shs
SMETHURST DOMINIC
Officer · Feb 03
3285 shs
HODGSON IAN
Chief Operating Officer · Feb 03
2415 shs
MORAN SEAN F
Chief Financial Officer · Jan 14
28082 shs
COHEN YUVAL
Chief Executive Officer · Jan 14
50000 shs
SMETHURST DOMINIC
Officer · Jan 14
28365 shs
HODGSON IAN
Chief Operating Officer · Jan 14
28365 shs
Last 90 days
Top Holders
Top 5: 39.91%Cormorant Asset Management,…
13.22%
$20.4M
Orbimed Advisors LLC.
9.01%
$13.9M
Aberdeen Group plc
7.45%
$11.5M
Octagon Capital Advisors LP
5.38%
$8.3M
Vanguard Group Inc
4.85%
$7.5M
As of Dec 31, 2025
Latest News
No related news yet